Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Trastuzumab Best Given Along with Chemotherapy

TOP - April 2010 Vol 3, No 2 published on June 10, 2010 in Breast Cancer

For women with human epidermal growth factor receptor type 2 (HER2)-positive early breast cancer, delaying trastuzumab until chemotherapy is completed may impair outcomes, according to findings from the landmark N9831 trial. The findings were presented by Edith Perez, MD, director of the Breast Cancer Program at the Mayo Clinic, Jacksonville, Florida.


The addition of 52 weeks of trastuzumab, either after standard chemotherapy with doxorubicin/cyclophosphamide followed by paclitaxel (AC-T) or concurrently with the paclitaxel, reduced the risk of breast cancer recurrence by 33% overall, but the benefit was significantly greater when trastuzumab was given concurrently with the paclitaxel portion of the chemotherapy, an approach that can now be recommended, Perez said.

"Often, the research community conducts studies that conclude with 'that was interesting, but let's do more research,'" she noted. "This is an important finding on how we can help prevent breast cancer recurrence and improve survival...This will clearly inform physician decision-making."

The N9831 trial, by the North Central Cooperative Trials Group, consisted of two comparisons. The first comparison included 2448 women randomized to chemotherapy alone or chemotherapy followed by trastuzumab. The proportion of women remaining diseasefree increased from 72% with chemotherapy alone to 80% with the addition of trastuzumab. The second comparison, which included 1903 women who were analyzed according to whether they received trastuzumab after chemo therapy (sequentially) or along with chemo therapy (concurrently with paclitaxel), continued for 52 weeks.

The sequential use of trastuzumab reduced recurrences by 33% over chemotherapy alone. At a median follow-up time of 5.3 years, 80% of women receiving 52 weeks of trastuzumab after chemotherapy were alive and disease-free, compared with 72% not receiving trastuzumab. But by giving trastuzumab concurrently with the paclitaxel portion of chemotherapy, the risk of recurrence was reduced by an additional 25%, compared with the sequential delivery of the drug. With concurrent trastuzumab, 84% of women were alive and disease-free compared with 80% of women treated sequentially, Perez reported.

"Based on a positive risk-benefit ratio, we recommend that adjuvant tras tuzumab be incorporated in a concurrent fashion with taxane chemotherapy," she said. 

Related Items
Olaparib Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Cryoablation Appears Safe and Effective in Low-Risk, Early-Stage Breast Cancer
William Ackerman
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in Breast Cancer
Pembrolizumab plus Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Abemaciclib plus Endocrine Therapy Offers Invasive Disease–Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Last modified: July 22, 2021